KRAS and colorectal carcinoma: Another selective HDAC6i, C1A, also showed potential antitumor activity against KRAS-mutated CRC in murine xenograft models [174] in combination with bortezomib that was characterized by inhibited degradation of misfolded proteins in proteasomes and decreased autophagy [175].